---
title: "OS Therapies Inc 2Q 2026: Net loss $8.63M, EPS $(0.20) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295978143.md"
description: "OS Therapies Inc reported a widened Q2 2026 net loss of $8.63M, or $(0.20) EPS, compared to $4.54M in the prior year. For the first half of 2026, the consolidated net loss reached $19.03M. Despite financial losses, the company highlighted clinical success with its OST-HER2 therapy meeting Phase IIb primary endpoints. OS Therapies is engaging with regulatory bodies for future submissions and has secured financing through direct offerings and notes to support ongoing R&D and trial activities."
datetime: "2026-08-14T21:13:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295978143.md)
  - [en](https://longbridge.com/en/news/295978143.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295978143.md)
generator: "portal-rs"
---

# OS Therapies Inc 2Q 2026: Net loss $8.63M, EPS $(0.20) — 10-Q Summary

OS Therapies Inc reported a second-quarter 2026 net loss of $8.63M, or $(0.20) per diluted share, compared with a net loss of $4.54M, or $(0.19) per share in the year-ago quarter. For the six months ended 2026 the company recorded a consolidated net loss of $19.03M, or $(0.46) per share, versus a six-month loss per share of $(0.35) in the prior year period.

**Financial Highlights**

-   Net loss: $8.63M for 2Q 2026, compared with a net loss of $4.54M in 2Q 2025 (loss widened ~90% YoY).
-   Six-month net loss: $19.03M for 6M 2026 (consolidated).
-   Diluted EPS: $(0.20) for 2Q 2026 versus $(0.19) in 2Q 2025; six-month diluted EPS $(0.46) versus $(0.35) year-ago (approximately 31% larger loss per share year-over-year for six months).

**Business Highlights**

-   Clinical Milestone — OST-HER2: Phase IIb met its primary endpoint, showing a 2.5-year overall survival of 75% versus a 47% historical control, with the therapy reported as well tolerated.
-   Regulatory Pathway & Plans: Ongoing engagements with the FDA, MHRA and EMA; company anticipates a Type C meeting with the FDA in September 2026 and plans MAA submissions in Q1 2027.
-   Pipeline Expansion: Continued development of the OST-tADC antibody‑drug conjugate platform and exploration of OST-HER2 combination regimens with HER2 antibodies for other solid tumors.
-   Operational and R&D focus: Increased R&D spending to compile regulatory package data; VAT recovery activity reduced reported R&D costs and helped extend cash runway.
-   Financing: Completed multiple financings, including a registered direct offering and secured notes, to fund ongoing clinical, regulatory and trial activities.

Original SEC Filing: OS Therapies Inc \[ OSTX \] - 10-Q - Aug. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [OSTX.US](https://longbridge.com/en/quote/OSTX.US.md)

## Related News & Research

- [OS Therapies management to attend H.C. Wainwright Global Investment Conference](https://longbridge.com/en/news/297776547.md)
- [OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance | OSTX Stock News](https://longbridge.com/en/news/297777149.md)
- [TCRX: Focus shifts to in vivo TCR-T solid tumor therapies, with two candidates advancing to clinical studies](https://longbridge.com/en/news/297776068.md)
- [Igua Sergipe board signs off Q2 2026 financial results](https://longbridge.com/en/news/297932404.md)
- [Alexandria Real Estate Equities declares Q3 2026 dividend of R$ 0.63 per unit](https://longbridge.com/en/news/297928934.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**